Positive and negative prediction of sustained virologic response at weeks 2 and 4 of treatment with albinterferon alfa-2b or peginterferon alfa-2a in treatment-naïve patients with genotype 1, chronic hepatitis C.

Abstract excerpt

BACKGROUND/AIMS: Albinterferon alfa-2b is a novel, long-acting, fusion polypeptide that is dosed q2wk or q4wk. The predictive value of early virologic response during albinterferon alfa-2b or peginterferon alfa-2a treatment was investigated in interferon-naïve patients with genotype 1, chronic hepatitis C. METHODS: Four hundred and fifty-eight patients were randomized to: albinterferon 900 or 1200 microg q2wk, or...

Topics

Share this publication in a Topic to start or enrich a Post.

• Share to Albumins
• Share to Algorithms